Navigation Links
Profound immune system discovery opens door to halting destruction of lupus
Date:12/13/2007

(New York, NY) A researcher funded by the Lupus Research Institute (LRI) has discovered an entirely new and powerful molecular switch that controls the inflammatory response of the immune system. The major finding, reported in the December 14th issue of the journal Cell, means that new methods can now be pursued to shut down uncontrolled inflammation, restore immune system regulation, and treat chronic autoimmune disorders such as lupus.

In autoimmunity, the immune system designed to fend off outside invaders mistakenly mounts an out-of-control destructive inflammatory attack against the bodys own tissues and organs. We have found an essential switch that controls immune inflammation, said LRI award recipient, Greg Lemke, PhD, professor of Molecular Neurobiology at the Salk Institute.

The breakthrough was supported at a critical juncture by the LRI, the nations only organization solely dedicated to funding novel and innovative science to prevent, treat, and cure lupus. Without the LRI, this project would have stoppedand a fundamental discovery in immunology would not have happened, Dr. Lemke said.

Major Implications

In this study, Dr. Lemke builds upon findings that he and his team previously reported, when he noticed that mice genetically engineered to be born without a tiny family of three receptorsTAM receptor tyrosine kinasesdeveloped an autoimmune illness similar to lupus in humans.

In the Cell article, Dr. Lemke now illustrates how these TAM receptors, under normal circumstances, are so critical in stopping the immune system from mounting an out-of-control inflammatory response against invading viruses and bacteria. When chemical messengers (cytokines) prompt immune cells to attack, he explains, they also activate TAM receptors, which then alert the cells to no longer react to the cytokines. This keeps the immune system orderly as well as relatively tranquil.

But in people with lupus and
'/>"/>

Contact: Liane Stegmaier
lstegmaier@lupusny.org
212-812-9881
Lupus Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Bursts of waves drive immune system soldiers toward invaders
2. Key to out-of-control immune response in lung injury found
3. Flies can turn off their immune response
4. How the plant immune system can drive the formation of new species
5. Auto immune response creates barrier to fertility; could be a step in speciation
6. Immune police recognize good and bad guys in the body
7. Agent that triggers immune response in plants is uncovered
8. Immune cells promote blood vessel formation in mouse endometriosis
9. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
10. The PIN codes of the immune system can be hacked
11. Pathogens use previously undescribed mechanism to sabotage host immune system

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...TY, Calif., Oct. 20 DigitalPersona...ntication solutions, today announced that WAND Cor...) software for quick-service restaurants, has inte...n POS and Classic POS solutions. WAND,s quick-serv...o boost cashier accountability and deter unauthori...
(Date:11/4/2009)...Calif., Oct. 23 GenVault Corporati...nagement for genomic discovery, medicine and ident...., GenVault,s President and CEO, will be presentin...n October 26th and 27th in La Jolla, CA. ,, Dur...verview of the company together with recent custom...
(Date:11/4/2009)...HILL Scientists at the University of North Caroli...rsity of California, San Francisco have developed ...ew target diseases for existing drugs. , The res...pares how similar the structures of all known drug...-- known as ligands -- of disease targets within t...
Breaking Biology News(10 mins):WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 1LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 2LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 3Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 1Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 2Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 3CVS pharmacys Transportation Operations Receives Two National Safety Awards 5326 1CVS pharmacys Transportation Operations Receives Two National Safety Awards 5326 2
... National Academy of Sciences , Yale researchers u... huge amounts of data on physical characteristics ...n habitats and metabolic activity in marine micro-...ed detail how environment influences molecular cha...bbed "metagenomics" progresses, scientists might b...
...threats to biodiversity and in many cases they hav... For their effective management it is important to...highest risk of being invaded. , The first map of...ion was published in the Wiley-Blackwell journal ...team of Czech, Spanish and British plant ecologist...
...your response to a radiological incident? How will... take care of us? How do we even know if we are ex...ll be addressed at the 42nd Midyear Topical Meetin...take place January 31-Feb 3, 2009 in San Antonio, ...The topic is "Recent Advances in Planning and Resp...
Other Biology News:Mixing genomics and geography yields insights into life and environment 242nd Mid-year Topical Meeting of the Health Physics Society 2
(Date:11/6/2009)..., Mass., Nov. 6 Myriant Technologi...loper and manufacturer of renewable bio-chemicals...chnology provider Uhde GmbH, one of the world,s le...nounced an alliance for the engineering, procureme...Succinic Acid plants based on renewable feedstocks...
(Date:11/6/2009)...D, Calif., Nov. 6 Intarcia Therape...ts ITCA 650 (DUROS® continuous delivery of ex...tes at the Ninth Annual Diabetes Technology Meetin...ewscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,... Via ITCA 650 Lowers Plasma Glucose, HbA1c and Red...
(Date:11/5/2009)...PANY, N.J., Nov. 5 DSM Pharmaceuti...nufacturing alliance with Galenix, Saint Jean D,Il...rcial scale manufacturing partner for Galenix comm...alenix will collaborate on business development op...hnologies, based on the strength of Galenix in dru...
(Date:11/5/2009)...OK, N.Y., Nov. 5 BioSpec...armaceutical company developing first-in-class col...cial results for the third quarter ended September...n September of this year, the FDA,s Arthritis Advi...of 12-0, the approval of XIAFLEX(TM) for the treat...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...ELPHIA, July 31 /PRNewswire-FirstCall/,-- Shire Li...ty,biopharmaceutical company announces results for...inancial Highlights, - Product sales up 40% to $7...4% to $409m - New product sales(1) $243m, 34% of ... to $776m - US GAAP earnings per ADS: loss $0.44 ...
... Health, a,global provider of products and service...th care, today announced a three-year agreement wi... pharmacy benefit managers,to serve as its primary...maceuticals, effective August 1., Prime Therapeut... drug,spend in 2007, and currently serves approxim...
...ook, MELVILLE, N.Y., July 31 Gentiva Health,Serv...provider of,comprehensive home health services, to... double-digit increases in Medicare revenues and a...(Logo: http://www.newscom.com/cgi-bin/prnh/200603...quarter ended June 29, 2008 included:, -- A 13% i...
Other Biology Technology:Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 2Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 3Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 4Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 5Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 6Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 7Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 8Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 9Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 10Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 11Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 12Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 13Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 14Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 15Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 16Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 17Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 18Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 19Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 20Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 21Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 22Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 23Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 24Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 25Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 26Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 27Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 28Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 29Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 30Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 31Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 32Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 33Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement 2Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3
Mouse Anti-Mouse Qa.m8 Monoclonal Antibody, Unconjugated, Clone 5035-24.1 from CEDARLANE Laboratories Limited
...s at the 9, 10, 12, and 13 positions. It is intend...ication of 13(S)-HODE by GC- or LC-mass spectromet...ic acid with plant and mammalian lipoxygenases. It...ells to the endothelium at concentrations around 1...
pcDNA4/His A B & C from Invitrogen
Adaptor Hind III - Sma I from Takara Mirus Bio
Biology Products: